Vaccine News and Research

Latest Vaccine News and Research

Experimental human monoclonal antibody shows striking benefit in patients with advanced melanoma

Early testing of an experimental human monoclonal antibody showed a striking benefit in patients with advanced melanoma, say researchers at The University of Texas M. D. Anderson Cancer Center, who presented their findings at the annual meeting of the American Society of Clinical Oncology.

7 Jun 2004

150 top scientists debate and offer expert advice on cutting edge vaccine research

More than 150 top scientists, researchers and public health experts from around the world will meet in Switzerland next week to present, debate and offer expert advice on cutting edge vaccine research and development, as well as vaccine policy and implementation.

3 Jun 2004

Latest version of the Approved List of Biological Agents published

The Advisory Committee on Dangerous Pathogens (ACDP) today published the latest version of the Approved List of Biological Agents.('The Approved List').

3 Jun 2004

Reliability of medical research in Britain today questioned by the general public

Doctors, patients and the general public depend on results of scientific research to provide information about the safety and effectiveness of medical treatments. Following the controversy surrounding the Andrew Wakefield study on the link between MMR vaccines and autism, the public is now considering the reliability of medical research in Britain today.

2 Jun 2004

Tuberculosis test kits order

Medical Services International Inc.has announced that it has received its first order for the VScan Tuberculosis (TB) rapid test kit from a prominent pharmaceutical company that produces Tuberculosis vaccines.

2 Jun 2004

New medical patent covering the generation of genetically enhanced therapeutic antigens

Morphotek, Inc. announced today the issuance of United States Patent 6,737,268 covering the generation of genetically enhanced therapeutic antigens.

2 Jun 2004

Malaria, Africa's biggest killer

It's Africa's biggest killer, but it's not HIV. It causes economic losses of US$12 billion per year, but it's not a war. And it has slowed African economic growth by around 1.3 per cent per annum, but it’s not a famine.

2 Jun 2004

Double-punch approach to vaccine design more effective

A study revealing new information about how viral proteins move between cells and alert the immune system suggests that a double-punch approach to vaccine design would make them more effective.

1 Jun 2004

Bird flu vaccine

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded two contracts to support the production and clinical testing of an investigational vaccine based on a strain of avian influenza, H5N1, which might have the potential to cause pandemic influenza.

27 May 2004

Blueprint for rational design of vaccines that induce desired T-cell responses

Investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have conducted studies in mice to gain a new picture of how the immune system’s “killer” T cells are prompted to destroy infected cells. Their insights provide a blueprint for rational design of vaccines that induce desired T-cell responses.

27 May 2004

Link between oral bacterium and premature babies

For years, scientists have noticed a particular oral bacterium can be found in the amniotic fluid of about 20 percent of women with premature babies.

27 May 2004

Research tests the efficacy of a smallpox vaccine candidate known as LC16m8

When used as an aerosolized weapon, smallpox could be controlled by a new vaccine under study at Saint Louis University School of Medicine, according to new data.

27 May 2004

Wyeth to seek rehearing of court ruling

Wyeth today said it would seek rehearing of a decision issued by the United States Court of Appeals for the Third Circuit reversing rulings by U.S. District Court Judge Harvey Bartle III of the Eastern District of Pennsylvania which excluded certain evidence in state court diet drug trials.

25 May 2004

$3.5 million grant to develop AIDS vaccinations

Researchers at the Vaccine and Gene Therapy Institute (VGTI) and the Oregon National Primate Research Center at Oregon Health & Science University have received a $3.5 million grant from the National Institutes of Health to develop new methods for vaccinating humans against human immunodeficiency virus (HIV), the virus that causes AIDS.

25 May 2004

Bacteria found in the mouth can block the HIV virus

Certain strains of bacteria that occur naturally in the human mouth can snare the HIV virus and even cells it has infected, according to researchers at the University of Illinois at Chicago College of Dentistry. They report their findings today at the 104th General Meeting of the American Society for Microbiology.

25 May 2004

Collusion seen after release of flawed vaccine-autism report

America's leading scientific organization investigating the risks that mercury-containing medical products pose to our children-has posted the results of an investigative analysis of several authors relied upon for the flawed Institute of Medicine (IOM) report issued last week attempting to purport a lack of evidence to the mercury-vaccine-autism link.

25 May 2004

Health-care providers can now review and update immunization records for patients online

Health-care providers can now review and update immunization records for patients online using the new and improved Web-based CHILD Profile Immunization Registry. The system is operated by the Department of Health and makes it easier for health-care professionals to keep track of immunization records.

25 May 2004

New AMA guide - Adults Only Vaccination: A Step-by-Step Guide

New for physicians is “Adults Only Vaccination: A Step-by-Step Guide," a comprehensive resource by the Immunization Action Coalition that covers all aspects of a vaccination program – from assessing vaccine indications and contraindications to determining billing codes.

24 May 2004

KETEK® (telithromycin) is highly active in vitro against Streptococcus pneumoniae (S. pneumoniae) isolates

Results from an ongoing surveillance study, PROTEKT US (Prospective Resistant Organism Tracking and Epidemiology of the Ketolide Telithromycin – United States) Year 2 (2001-2002), suggest that KETEK® (telithromycin) is highly active in vitro against Streptococcus pneumoniae (S. pneumoniae) isolates, including those resistant to other antimicrobial agents.

24 May 2004

Canadian healthcare policy under the microscope

Healthcare policies and programs come and go. Yet the professionals who design the medical services we use are rarely mentioned in the general healthcare debates. That's about to change.

23 May 2004